4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
3 December 2025
3 December 2025
3 December 2025
2 December 2025
1 December 2025
1 December 2025
Latest Features
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Latest Conference Videos
Americas
Brazil’s pharmaceutical IP landscape is shifting fast, and Juliana Neves of Licks unpacks how new reforms, guidelines, and rulings are resetting the strategic ground rules for innovators.
Unified Patent Court
Powell Gilbert experts share insights on how the Unified Patent Court is taking shape after two years in operation, in this session from LSPN.
Americas
This LSPN panel brings together experts from Troutman Pepper Locke, Sauvegarder Investment Management, Beam Therapeutics, Editas Med, and Takeda to explore the expanding role of IP lawyers in the life sciences industry.
Americas
Jennifer Che of Eagle IP explores key IP challenges in China and offers practical strategies to address them, covering topics such as AI, patent linkage and export controls in this LSPN session.
More News
27 November 2025 The Court of Appeal has overturned a ruling that revoked the pharma company’s cholesterol-lowering antibody patent, clarifying key principles for assessing inventive step.
27 November 2025 Director Squires rescinds previous guidelines and clarifies that there is no separate, modified inventorship standard for AI-assisted inventions.
27 November 2025 Even when legal teams do include women, the judges say they don’t always see or hear them, emphasising that visibility is critical for aspiring advocates.
26 November 2025 Balancing tight budgets while keeping up with fast-changing biosimilar rules is all in a day’s work for Novartis’s R&D IP team, but how do they stay on top of it all?
25 November 2025 Regeneron and Bayer suffered a UK setback as the court followed others in Europe in its interpretation of the so-called SPC manufacturing waiver.
24 November 2025 A regulatory counsel with nine years at the FDA and over two decades of patent experience has joined a firm in Washington, DC.
24 November 2025 AI content in new enquiries is a growing problem, says the man leading the UK association’s AI Committee. Sarah Speight reports.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox